Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 17/20 | 0.52 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8251107 | 0.90 | TRPV1 (0.52) | TRPV1FYNRET | |
| SCHEMBL4871515 | 0.87 | TRPV1 (0.57) | TRPV1RET | |
| SCHEMBL4871886 | 0.83 | HTR2A (0.47) | TRPV1METKDR | |
| SCHEMBL4868221 | 0.82 | HTR2A (0.48) | TRPV1 | |
| SCHEMBL6001093 | 0.81 | TRPV1 (0.49) | TRPV1 | |
| SCHEMBL6001816 | 0.81 | TRPV1 (0.49) | TRPV1 | |
| SCHEMBL4864851 | 0.78 | TRPV1 (0.52) | TRPV1 | |
| SCHEMBL17298755 | 0.77 | AR (0.51) | TRPV1KDR | |
| SCHEMBL4864806 | 0.77 | PIP4K2A (0.50) | TRPV1KDR | |
| SCHEMBL2846226 | 0.77 | TRPV1 (0.57) | TRPV1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006062981-A2 | ANTAGONISTS TO THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-06-15 | — | — | WO | claimed |
| US-20060128710-A1 | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBOTT LABORATORIES | 2006-06-15 | — | — | US | claimed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| WO-2008046788-A1 | SKIN BENEFIT COMPOSITIONS WITH A VANILLOID RECEPTOR ANTAGONIST | UNILEVER PLC (GB) | 2008-04-24 | — | — | WO | disclosed |
| US-20080095720-A1 | Vitamin A, Vitamin B3, humectant, aloe vera, pigmentary or sunscreen grade metal oxide, Vitamin C, resorcinol, an antisebum agent, or a hydroxy fatty acid and capsazepine; wrinkle resistance cosmetics | CONOPCO, INC., D/B/A UNILEVER (US) | 2008-04-24 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2006118598-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-1713807-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1697361-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | Renovis, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060128710-A1 | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBOTT LABORATORIES | 2006-06-15 | — | — | US | disclosed |
| US-20050277643-A1 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | EVOTEC AG (DE) | 2005-12-15 | — | — | US | disclosed |
| US-20050215572-A1 | N-(4-tert-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidin-4-yl]-amine; antiinflammatory agents treating pain, inflammation, traumatic injury, arthritis, Parkinson's disease, Alzheimer's disease, stroke, asthma, myocardial infarction | EVOTEC AG (DE) | 2005-09-29 | — | — | US | disclosed |
| WO-2005070929-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050165032-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2005066171-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128710-A1 | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof | OPRL1, AVPR1A, AVPR2 | TRPV1 5/4885FYN 1570/4885MET 4535/4885 |
| US-20050165032-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885FYN 285/4885MET 1059/4885 |
| US-20050215572-A1 | N-(4-tert-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidin-4-yl]-amine; antiinflammatory agents treating pain, inflammation, traumatic injury, arthritis, Parkinson's disease, Alzheimer's disease, stroke, asthma, myocardial infarction | PARK7, PTGIS, PTGES | TRPV1 224/4885FYN 685/4885MET 4039/4885 |
| US-20080095720-A1 | Vitamin A, Vitamin B3, humectant, aloe vera, pigmentary or sunscreen grade metal oxide, Vitamin C, resorcinol, an antisebum agent, or a hydroxy fatty acid and capsazepine; wrinkle resistance cosmetics | RBP4, ALOX15, ALOX15B | TRPV1 15/4885FYN 4693/4885MET 3610/4885 |
| US-20050277643-A1 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | TRPV1, TRPV3, TRPA1 | TRPV1 1/4885FYN 1853/4885MET 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.